NEWS
LATEST
FULL LIST
-
United Therapeutics Reports Breakthrough Phase 1 Results for Bioengineered Liver Support System
United Therapeutics has announced positive Phase 1 clinical results for miroliverELAP®, marking the world’s first FDA-cleared human trial of a bioengineered liver support system. Developed by its subsidiary Miromatrix Medical, the platform represents a major milestone in regenerative medicine and organ manufacturing. The results suggest that engineered liver constructs may soon offer lifesaving temporary support…
-
Aspect Biosystems and Novo Nordisk Deepen Partnership to Advance Curative Diabetes Therapies
In a major step forward for regenerative medicine and diabetes care, Aspect Biosystems and Novo Nordisk have announced a new phase of their strategic partnership focused on developing potentially curative cell-based therapies for diabetes. The expanded collaboration builds on a relationship launched in 2023 and reflects growing momentum in the effort to replace, repair, or…
-
WFIRM Secures ARPA-H Award to Advance On-Demand Bioprinted Kidneys
The Wake Forest Institute for Regenerative Medicine (WFIRM) has secured up to $24.8 million in federal funding over five years to advance one of regenerative medicine’s most ambitious goals: creating fully functional, bioprinted kidneys on demand. The award comes through the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program of the Advanced Research Projects Agency for…
-
Wyss Institute-Led Team Wins ARPA-H PRINT Award to Engineer Universal, Transplant-Ready Liver Grafts known as ImPLANT
Wyss-Led ARPA-H Project Aims to Deliver Universal, Off-the-Shelf Liver Grafts A multidisciplinary team led by the Wyss Institute at Harvard University has secured a major award from the Advanced Research Projects Agency for Health (ARPA-H) to develop implantable, immune-compatible liver grafts that could transform treatment for liver failure. Announced in January 2026, the initiative—known as…
-
Carnegie Mellon Team Wins $28.5M ARPA-H Award to Bioprint Regenerative Human Livers
A research team led by Adam Feinberg, Professor at Carnegie Mellon University and CTO and co-founder of FluidForm Bio, has received up to $28.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a functional, 3D bioprinted liver for patients suffering from acute liver failure. The award, part of ARPA-H’s PRINT (Personalized…
-
ARPA-H’s $176M Bet on Bioprinted Organs: Inside the PRINT Program’s Push to End Transplant Shortages
The promise of printing fully functional, immune-matched human organs has long been a defining ambition of regenerative medicine. Now, that ambition is moving from theory to large-scale execution. This week, Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services (HHS), announced the first awardees of its ambitious…
-
The Business of Biofabrication: What 2025 Taught Us
If the last decade of biofabrication was defined by technical possibility, 2025 was the year the business reality became unavoidable. Across funding announcements, platform launches, government contracts, and quiet shutdowns, one message became clear: biofabrication is no longer judged by what it can build, but by what it can sell, scale, and sustain. This year,…
-
restor3d Completes First Clinical Cases of Fully Personalized 3D-Printed Knee Replacement System
restor3d has announced a major clinical milestone: the first surgeries using the iTotal Identity™ CR 3DP Porous Fully Personalized Total Knee Replacement System, the first cementless knee implant system built entirely around patient-specific design and advanced 3D-printed porous structures. This marks a transformative moment in orthopedics—a shift from standardized implants to fully individualized joint replacements…
-
Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development
Revalia Bio, a Yale-born startup redefining drug development through real human donor tissue, has secured a landmark ~$30 million U.S. government contract—one of the largest ever awarded to a seed-stage biotechnology company. The announcement marks a turning point not only for Revalia, but for the broader movement away from animal-model drug development and toward human-first…
-
Inside Curi Bio’s Human Tissue Platforms: How They Work, What the $10M Series B Will Accelerate, and Why It Matters
In a recent Series B financing round led by DreamCIS, Curi Bio announced it has raised $10 million to expand its human-relevant bioengineering platforms for drug discovery. What exactly has Curi built today? How do its technologies work? And where will this new capital be deployed? Below, we break down the mechanisms, applications, and strategic…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 